Flecainide

Drug Profile

Flecainide

Alternative Names: Almarytm; Apocard; Aristocor; Diondel; Flecaine; Flecainide acetate; Tambocor

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator 3M Pharmaceuticals
  • Developer 3M Pharmaceuticals; Eisai Co Ltd
  • Class Class Ic antiarrhythmics; Piperidines; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Arrhythmias; Paroxysmal atrial fibrillation; Paroxysmal atrial flutter; Paroxysmal supraventricular tachycardia; Ventricular arrhythmias; Ventricular tachycardia

Most Recent Events

  • 05 Aug 2016 Meda has been acquired by Mylan
  • 26 Jun 2015 Launched for Paroxysmal supraventricular tachycardia, paroxysmal atrial fibrillation, ventricular tachycardia and paroxysmal atrial flutter (In children) in Japan (PO)
  • 19 Feb 2015 Registered for Paroxysmal atrial fibrillation, Paroxysmal atrial flutter, Paroxysmal supraventricular tachycardia and Ventricular tachycardia (In children) in Japan (PO, Granule)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top